title: A prospective randomized study on the mobilization of CD34+ cells comparing continuous intravenous vs subcutaneous administration of rhG-CSF in normal donors.
abstract: The efficacy of mobilizing peripheral blood progenitor cells (PBPC) with continuous intravenous (c.i.v.) administration of rhG-CSF was randomly compared to subcutaneous (s.c.) administration, in 15 normal donors in each arm of the study for 6 days. The percentage and absolute numbers of CD34+ cells in the c.i.v. and s.c. groups increased maximally at day 3 and 5, respectively, when compared with the steady-state (day 0) level. Peak CD34+ cell levels were achieved on day 3 in the c.i.v. group, with more rapid results than in the s.c. group (49.3/microl vs 35.9/microl, P=0.043). Plasma rhG-CSF levels declined progressively during mobilization in each group as the WBC increased. The serum level of rhG-CSF did not correlate with CD34+ cell counts in the peripheral blood. Toxicity profiles in the c.i.v. and s.c. groups were similar. Each regimen was effective in successfully mobilizing the target CD34 cell number.
authors.affiliation: Department of Hematology-Oncology, Ewha Women's University, Seoul, Republic of Korea.
authors.forename: K-E
authors.initials: KE
authors.lastname: Lee
authors.forename: Y C
authors.initials: YC
authors.lastname: Mun
authors.forename: S-H
authors.initials: SH
authors.lastname: Nam
authors.forename: J M
authors.initials: JM
authors.lastname: Kwon
authors.forename: S M
authors.initials: SM
authors.lastname: Lee
authors.forename: M-A
authors.initials: MA
authors.lastname: Lee
authors.forename: E-S
authors.initials: ES
authors.lastname: Yoo
authors.forename: J-Y
authors.initials: JY
authors.lastname: Ahn
authors.forename: J-H
authors.initials: JH
authors.lastname: Kim
authors.forename: C-M
authors.initials: CM
authors.lastname: Seong
mesh_terms: D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34 / Q000096:biosynthesis*; D002469:Cell Separation; D005260:Female; D005434:Flow Cytometry; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D016130:Immunophenotyping; D007262:Infusions, Intravenous / Q000379:methods*; D007279:Injections, Subcutaneous / Q000379:methods*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D010641:Phenotype; D011446:Prospective Studies; D011994:Recombinant Proteins; D013997:Time Factors
chemical_list: D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor